Dishman Carbogen, Client to Invest CHF 25M to Expand Swiss Sites

10 Jun 2025 CW Team

The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC), enabling CARBOGEN AMCIS to meet rising global demand. As part of the agreement, both facilities will see significant equipment and infrastructure enhancements, including:

Aarau site: installation of 850-litre reactors and 0.4 m² agitated filter dryers with supporting equipment. Completion is expected by Q1 2027.
Neuland site: installation of 850-litre reactors and 0.4 m² agitated filter dryers with auxiliary systems. Completion is anticipated by Q3 2027.

This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021 to develop a site extension at the Bubendorf site in Switzerland, reinforcing the strength of the relationship and their shared commitment to long-term growth.

“This expansion demonstrates our ability to scale alongside our customers, responding to the increasing demand for complex and high-value compounds such as ADC drug linkers,” said Stephan Fritschi, CEO at CARBOGEN AMCIS. “We’re proud to continue building on our strong trust and technical collaboration foundation.”

CARBOGEN AMCIS is recognised for its robust capabilities in handling highly potent compounds, offering end-to-end support from process development to commercial supply. The new investments will further strengthen the company’s infrastructure to deliver high-quality manufacturing services in line with cGMP and global regulatory expectations.

“By investing in both Aarau and Neuland, we’re ensuring that our infrastructure keeps pace with our customers’ ambitions,” said Carl Baker, Vice President Business Unit Drug Substance. “These upgrades will allow us to seamlessly manage increased volumes while maintaining the operational excellence and containment controls required for highly potent APIs and advanced therapies.”

With facilities across Switzerland, France, the UK, the Netherlands, and China, CARBOGEN AMCIS continues to expand its global footprint while delivering flexible, integrated CDMO solutions to pharmaceutical and biopharmaceutical innovators worldwide.

The Company’s subsidiary, CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, is pleased to announce a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland.The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC), enabling CARBOGEN AMCIS to meet rising global demand. As part of the agreement, both facilities will see significant equipment and infrastructure enhancements, including:Aarau site: installation of 850-litre reactors and 0.4 m² agitated filter dryers with supporting equipment. Completion is expected by Q1 2027.Neuland site: installation of 850-litre reactors and 0.4 m² agitated filter dryers with auxiliary systems. Completion is anticipated by Q3 2027.This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021 to develop a site extension at the Bubendorf site in Switzerland, reinforcing the strength of the relationship and their shared commitment to long-term growth.“This expansion demonstrates our ability to scale alongside our customers, responding to the increasing demand for complex and high-value compounds such as ADC drug linkers,” said Stephan Fritschi, CEO at CARBOGEN AMCIS. “We’re proud to continue building on our strong trust and technical collaboration foundation.”CARBOGEN AMCIS is recognised for its robust capabilities in handling highly potent compounds, offering end-to-end support from process development to commercial supply. The new investments will further strengthen the company’s infrastructure to deliver high-quality manufacturing services in line with cGMP and global regulatory expectations.“By investing in both Aarau and Neuland, we’re ensuring that our infrastructure keeps pace with our customers’ ambitions,” said Carl Baker, Vice President Business Unit Drug Substance. “These upgrades will allow us to seamlessly manage increased volumes while maintaining the operational excellence and containment controls required for highly potent APIs and advanced therapies.”With facilities across Switzerland, France, the UK, the Netherlands, and China, CARBOGEN AMCIS continues to expand its global footprint while delivering flexible, integrated CDMO solutions to pharmaceutical and biopharmaceutical innovators worldwide.

Infrastructure Urban

13 Oct 2025

Daikin Boosts Haryana’s Innovation Push with Rs 10 billion R&D Plan

Japanese multinational Daikin Industries has committed an investment of Rs 10 billion to set up a new research and development centre in Haryana. The proposed facility will focus on advanced technologies and sustainable industrial solutions, marking a significant boost to the state’s innovation and industrial ecosystem. The announcement follows the signing of a Memorandum of Understanding (MoU) in Osaka, Japan, during a visit by a Haryana government delegation held from October 6 to 8. The MoU was signed by Amit Kumar Agrawal, Commissioner and Secretary, Industries and Commerce Department, ..

Building Material

13 Oct 2025

Lloyds Metals to Build Rs 250 billion Steel Plant in Gadchiroli

Lloyds Metals & Energy Limited (LMEL) has announced an investment of Rs 250 billion aimed at transforming Gadchiroli in Maharashtra from a region once associated with the red corridor into a key industrial and growth hub. The company’s plans are centred on establishing an integrated steel production ecosystem, which will contribute significantly to regional development and employment. As part of its expansion strategy, LMEL is setting up a 4.5-million-tonne blast furnace in Gadchiroli, scheduled for completion by 2027–28, along with another 1.2-million-tonne facility in Chandrapur by 2029..

Infrastructure Urban

13 Oct 2025

UPI Crosses 500 Million Users, Fuels MSME and Digital Growth

The Unified Payments Interface (UPI) has achieved a new milestone, surpassing 500 million consumers and 65 million merchants across India. The platform, developed by the National Payments Corporation of India (NPCI), has expanded its reach to nearly 99 percent of the country’s pin codes, underlining its deep penetration into both urban and rural markets. According to a report by NPCI and the Boston Consulting Group (BCG) launched during the Global Fintech Fest 2025, UPI has evolved from being a digital payments mechanism into a key enabler of financial inclusion and small business growth. I..